Xenon Competitors
| XENE Stock | USD 41.45 0.44 1.07% |
Xenon Pharmaceuticals vs Legend Biotech Correlation
Very good diversification
The correlation between Xenon Pharmaceuticals and LEGN is -0.35 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Xenon Pharmaceuticals and LEGN in the same portfolio, assuming nothing else is changed.
Moving against Xenon Stock
As of February 3, 2026, Return On Tangible Assets is expected to decline to -0.35. In addition to that, Return On Capital Employed is expected to decline to -0.44. At present, Xenon Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 9.1 M, whereas Return On Tangible Assets are forecasted to decline to (0.35).Xenon Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Xenon Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Xenon and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Xenon Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Xenon Stock performing well and Xenon Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Xenon Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CNTA | 2.31 | 0.05 | 0.00 | 0.20 | 2.67 | 4.97 | 26.54 | |||
| APGE | 1.97 | 0.20 | 0.07 | 0.18 | 2.68 | 4.52 | 23.21 | |||
| AAPG | 2.53 | (0.52) | 0.00 | (4.66) | 0.00 | 5.25 | 16.72 | |||
| RARE | 3.00 | (0.35) | 0.00 | (0.16) | 0.00 | 7.73 | 51.23 | |||
| CELC | 2.35 | 0.62 | 0.27 | 1.17 | 1.97 | 6.70 | 17.89 | |||
| ZLAB | 1.86 | (0.66) | 0.00 | (2.24) | 0.00 | 4.56 | 10.32 | |||
| CGON | 2.96 | 0.38 | 0.13 | 0.50 | 2.59 | 5.15 | 33.66 | |||
| SRRK | 2.90 | 0.72 | 0.25 | 0.99 | 2.40 | 5.92 | 31.68 | |||
| TVTX | 2.83 | 0.17 | 0.05 | 0.16 | 3.48 | 6.31 | 33.22 | |||
| LEGN | 2.27 | (0.92) | 0.00 | 5.46 | 0.00 | 3.83 | 19.65 |
Cross Equities Net Income Analysis
Compare Xenon Pharmaceuticals and related stocks such as Centessa Pharmaceuticals, Apogee Therapeutics, and Ascentage Pharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTA | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (10.7 M) | (381.9 M) | (216.2 M) | (151.1 M) | (235.8 M) | (212.2 M) | (222.8 M) |
| APGE | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (84 M) | (182.1 M) | (163.9 M) | (155.7 M) |
| AAPG | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (118.5 M) | (345.3 M) | (1.5 B) | (677.6 M) | (782.4 M) | (882.9 M) | (925.6 M) | (405.4 M) | (364.9 M) | (383.1 M) |
| RARE | (6.8 M) | (6.8 M) | (16.3 M) | (35.1 M) | (59.8 M) | (145.6 M) | (245.9 M) | (302.1 M) | (197.6 M) | (402.7 M) | (186.6 M) | (454 M) | (707.4 M) | (606.6 M) | (569.2 M) | (512.3 M) | (486.7 M) |
| CELC | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (3.3 M) | (6.3 M) | (7.5 M) | (7.4 M) | (9.5 M) | (29.6 M) | (40.4 M) | (63.8 M) | (111.8 M) | (100.6 M) | (95.6 M) |
| ZLAB | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (37.5 M) | (50.4 M) | (139.1 M) | (183.4 M) | (268.9 M) | (704.5 M) | (443.3 M) | (334.6 M) | (257.1 M) | (231.4 M) | (243 M) |
| CGON | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (35.4 M) | (48.6 M) | (88 M) | (79.2 M) | (75.3 M) |
| SRRK | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (25 M) | (49.3 M) | (49.7 M) | (85 M) | (131.8 M) | (131.6 M) | (165.8 M) | (246.3 M) | (221.7 M) | (210.6 M) |
| TVTX | (18.3 K) | (14.8 K) | (30.3 M) | (33.8 M) | (110.9 M) | 117.2 M | (47.9 M) | (59.7 M) | (102.7 M) | (146.4 M) | (169.4 M) | (180.1 M) | (278.5 M) | (111.4 M) | (321.5 M) | (289.4 M) | (274.9 M) |
| LEGN | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | (2.8 M) | (101.6 M) | (266.4 M) | (403.6 M) | (446.3 M) | (518.3 M) | (177 M) | (159.3 M) | (167.3 M) |
Xenon Pharmaceuticals and related stocks such as Centessa Pharmaceuticals, Apogee Therapeutics, and Ascentage Pharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Xenon Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Xenon Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Xenon Pharmaceuticals Competitive Analysis
The better you understand Xenon Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Xenon Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Xenon Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Xenon Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Xenon Pharmaceuticals Competition
Xenon Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Xenon Pharmaceuticals in relation to its competition. Xenon Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Xenon Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Xenon Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Xenon Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Xenon Pharmaceuticals position
In addition to having Xenon Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Real Estate Thematic Idea Now
Real Estate
Publicly traded companies that are involved in real estate development, property maintenance and management of real estate investment trusts (REIT) funds. The Real Estate theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Xenon Pharmaceuticals Correlation with its peers. For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Will Biotechnology sector continue expanding? Could Xenon diversify its offerings? Factors like these will boost the valuation of Xenon Pharmaceuticals. Anticipated expansion of Xenon directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Xenon Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.82) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Xenon Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Xenon's accounting equity. The concept of intrinsic value—what Xenon Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Xenon Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Xenon Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.